Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Orthop. Sep 18, 2014; 5(4): 504-511
Published online Sep 18, 2014. doi: 10.5312/wjo.v5.i4.504
Published online Sep 18, 2014. doi: 10.5312/wjo.v5.i4.504
Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis
Lisa M Lundquist, College of Health Professions, Mercer University, Atlanta, GA 30341, United States
Sabrina W Cole, School of Pharmacy, Wingate University, Wingate, NC 28174, United States
Martha L Sikes, College of Health Professions, Mercer University, Atlanta, GA 30341, United States
Author contributions: Lundquist LM, Cole SW and Sikes ML wrote and edited the manuscript.
Correspondence to: Lisa M Lundquist, PharmD, BCPS, College of Health Professions, Mercer University, 3001 Mercer University Drive, Atlanta, GA 30341, United States. lundquist_lm@mercer.edu
Telephone: +1-678-5476208 Fax: +1-678-5476231
Received: December 29, 2013
Revised: March 26, 2014
Accepted: May 31, 2014
Published online: September 18, 2014
Revised: March 26, 2014
Accepted: May 31, 2014
Published online: September 18, 2014
Core Tip
Core tip: Tofacitinib, a Janus kinase inhibitor, is a targeted, synthetic, disease-modifying antirheumatic drug (DMARD) approved for the treatment of moderately to severely active rheumatoid arthritis in patients who have had an inadequate response to methotrexate. In numerous phase 2 and 3 trials, tofacitinib has proven to be safe and effective as monotherapy or in combination with methotrexate or other non-biologic DMARDs.